Bernd W. Scheithauer
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bernd W. Scheithauer.
Cancer | 1997
Stephen W. Coons; Peter C. Johnson; Bernd W. Scheithauer; Allan J. Yates; Dennis K. Pearl
Accurate histologic diagnosis of gliomas is fundamental to proper patient management and to the interpretation of basic and clinical investigations. Diagnostic accuracy and reproducibility are compromised by the subjective histologic criteria currently used to classify and grade gliomas.
Cancer | 1998
Arie Perry; Scott L. Stafford; Bernd W. Scheithauer; Vera J. Suman; M B S Christine Lohse
Despite the availability of clinical and pathologic parameters of prognosis, the behavior of an individual meningioma may be difficult to predict. In a recent review of gross totally resected (GTR) meningiomas, the authors found strong associations between microscopic brain invasion, increased mitotic rate (≥4/10 high‐power fields), the presence of at least 3 of 4 morphologic variables (sheeting, hypercellularity, macronucleoli, and small cells), and decreased recurrence free survival (RFS). In this study, they assessed the prognostic value of three ancillary techniques: DNA flow cytometry, MIB‐1 labeling, and p53 protein expression.
Cancer | 1998
Tahseen Al-Saleem; Lisa L. Wessner; Bernd W. Scheithauer; Kathleen Patterson; E. Steven Roach; Stephen J. Dreyer; Keita Fujikawa; Johannes Bjornsson; Jay Bernstein; Elizabeth Petri Henske
The tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by seizures, mental retardation, and benign tumors of the brain, heart, skin, and kidney. Malignant tumors also can occur in patients with tuberous sclerosis, particularly in the kidney, although they occur less frequently than benign tumors. The types of malignancy that occur in TSC have not been characterized fully.
Cancer | 1993
Steven E. Schild; Bernd W. Scheithauer; Paula J. Schomberg; C. Christopher Hook; Patrick J. Kelly; R N Lorraine Frick; Jay S. Robinow; Steven J. Buskirk
Background. Pineal parenchymal tumors are rare; therefore, only limited clinical data regarding their behavior is available. This study was performed to provide further information regarding the pathologic features, clinical behavior, and response to therapy of these tumors.
Cancer | 1993
Peter A. Forsyth; Edward G. Shaw; Bernd W. Scheithauer; Judith R. O'Fallon; Donald D. Layton; Jerry A. Katzmann
Background. Supratentorial pilocytic astrocytomas are uncommon tumors, the prognosis and management of which have been controversial.
Cancer | 1996
Steven E. Schild; Bernd W. Scheithauer; Michael G. Haddock; William W. Wong; Mark K. Lyons; Lawrence B. Marks; Margaret G. Norman; Peter C. Burger
This study examined the outcome of patients with histologically confirmed pineal region tumors.
Cancer | 2001
Jan C. Buckner; Paula J. Schomberg; William L. McGinnis; Terrence L. Cascino; Bernd W. Scheithauer; Judith R. O'Fallon; Roscoe F. Morton; Steven A. Kuross; James A. Mailliard; Alan K. Hatfield; John T. Cole; Preston D. Steen; Albert M. Bernath
The current study was conducted to determine whether the addition of interferon‐α (IFN‐α) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high‐grade glioma.
Cancer | 1996
Kalman Kovacs; Bernd W. Scheithauer; Eva Horvath; Ricardo V. Lloyd
Although numerous attempts have been made, the classification of pituitary neoplasms remains controversial.
Cancer | 1998
Evanthia Galanis; Jan C. Buckner; Bernd W. Scheithauer; David W. Kimmel; Paula J. Schomberg; David G. Piepgras
Meningeal hemangiopericytoma is an uncommon neoplasm with a high propensity for recurrence. The purpose of this study was to analyze the efficacy of different treatment options in patients with recurrent disease.
Cancer | 1999
Arie Perry; Bernd W. Scheithauer; Scott L. Stafford; Christine M. Lohse; Peter C. Wollan
Due to the rarity of malignancy in meningiomas, prior studies have been limited to small series. Controversies regarding the definition of malignant meningioma have complicated matters further. Although histologic anaplasia and extracranial metastasis are established criteria, the former is difficult to define and the latter represents a clinical finding. Traditionally, brain invasion has also been accepted, although this has recently been debated. In a prior series, the authors were unable to prove that 23 meningiomas that had invaded the brain were more aggressive than atypical meningiomas.